NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION

The present invention provides nucleoside aryl phosphoramidates which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
   IPC: A61K 31/70 (2006.01); C07H 19/00 (2006.01)

   USPC: 514/45, 46, 47, 48; 536/22.1, 27.1, 27.21, 27.6, 27.61
   According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

   Minimum documentation searched (classification system followed by classification symbols)
   U.S.: 514/45, 46, 47, 48; 536/22.1, 27.1, 27.21, 27.6, 27.61

   Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 6,638,919 B2 (McCUIGAN et al) 28 October 2003 (28.10.2003), see entire patent.</td>
<td>1-16</td>
</tr>
<tr>
<td>A</td>
<td>US 6,475,985 B1 (WAGNER et al) 5 November 2002 (5.11.2002), see entire patent</td>
<td>1-16</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C.
☐ See patent family annex.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent published on or after the international filing date
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed
  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "&" document member of the same patent family

Date of the actual completion of the international search: 15 March 2006 (15.03.2006)
Date of mailing of the international search report: 11 April 2006

Name and mailing address of the ISA/US
Mail Stop PTC, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (571) 273-3201

Authorized officer
Michael C. Henry
Telephone No. 703 308-1955

Form PCT/ISA/210 (second sheet) (April 2005)